Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor Microenvironment PET/CT Imaging in Aggressive Lymphoma
NCT07657494Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of [18F]AlF-NOTA-FAPI-04 and Al18F-NOTA-grazytracer + 68Ga-grazytracer in aggressive lymphoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Predictive Performance of FAPI PET/CT for Treatment Response or Disease Progression. Started Jul 2024; status: recruiting.
02
Drugs
[18F]AlF-NOTA-FAPI-04Al18F-NOTA-grazytracer + 68Ga-grazytracer
03
Conditions
aggressive lymphoma
Beyond the preview
Go deeper on NCT07657494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657494.